1. Home
  2. Approved trials
  3. » فارسی

Randomized, single-dose, crossover comparative bioequivalence study of the Gefitinib 250 mg tablets produced by Kimia pharmaceutical Co versus Iressa® (AstraZeneca company) in 30 healthy males under fasting conditions

Protocol summary

Study aim
To demonstrate bioequivalence of single dose test formulation of Kimia pharmaceutical Co Gefitinib 250 mg tablets versus Iressa® (AstraZeneca co.).
Design
Single dose, randomized and crossover bioequivalence study of Gefitinib 250 mg tablets (Kimia Co.) with Iressa® in 30 healthy male in two groups under fasting condition.Data will be analyzed with Excel and SPSS software.
Settings and conduct
Study place: Drug Applied Research Center affiliated to Tabriz University of Medical Science. Place for Blood and plasma sample analysis: Imam Reza Medical Research and Trainning Hospital. 30 healthy male volunteers received each of two test or reference Gefitinib 250 mg tablets in random sequence according to the randomization schedule. The interval between receiving the medicine (washout period) is 14 days, If the first sequence receives Iranian medicine, they will receive brand medicine. Blood samples will be taken from all participants before receiving the drug and 120 hours after that at determined time points: 0, 0.5، 1، 2، 3، 4، 5، 6، 8، 12، 24 ،48 ،72 ،96 and 120 hours.
Participants/Inclusion and exclusion criteria
Healthy male subjects in the age range of 18-60 years and BMI (Body Mass Index) of 18.5-30. Exclusion criteria: subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg; any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function or a history of TB, epilepsy, asthma, DM; psychosis or glaucoma and regular smoker.
Intervention groups
Intervention group (Test): Gefitinib 250 mg tablets by Kimia Co. is the test product. In each period, 15 of 30 subjects will be given single oral dose of this product. Control group (Reference): Iressa® (AstraZeneca co.) is the reference product. In each period, 15 of 30 subjects will be given single dose of this product.
Main outcome variables
Peak Plasma Concentration (Cmax); Area under the concentration-time curve (AUC).

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20200407046981N6
Registration date: 2021-03-24, 1400/01/04
Registration timing: registered_while_recruiting

Last update: 2021-03-24, 1400/01/04
Update count: 0
Registration date
2021-03-24, 1400/01/04
Registrant information
Name
Fatima Molavi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3336 2700
Email address
molavif@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-05-04, 1399/02/15
Expected recruitment end date
2021-08-06, 1400/05/15
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Randomized, single-dose, crossover comparative bioequivalence study of the Gefitinib 250 mg tablets produced by Kimia pharmaceutical Co versus Iressa® (AstraZeneca company) in 30 healthy males under fasting conditions
Public title
Study of absorption and elimination rate of Gefitinib 250 mg tablets in comparison with standard tablet of Iressa® (AstraZeneca company).
Purpose
Health service research
Inclusion/Exclusion criteria
Inclusion criteria:
The weight limit for each volunteer is between 60 and 100 kg. All volunteers must be non-smokers. They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
Exclusion criteria:
Known hypersensitivity or idiosyncratic reaction to Erlotinib or any ingredients. Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg Regular smoker who smokes more than ten cigarettes daily. Taking any medicine during two week before dosing.
Age
From 18 years old to 60 years old
Gender
Male
Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: 30
More than 1 sample in each individual
Number of samples in each individual: 15
Candidates of the sequences must take one of the Iranian or brand drugs, if the first sequence of the volunteers received the Iranian drug after the washout period, they must receive the brand drug. In fact,every single volunteers is used as control for himself.
Randomization (investigator's opinion)
Randomized
Randomization description
Individuals will be recruited with advertising. 30 volunteers will be allocated to two sequences randomly by lottery method.The number was allocated according to their entrance to volunteers' list in screening day.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Tabriz University of Medical Science
Street address
Third floor, central building No. 2, Golgasht street, Tabriz University of Medical Science, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Approval date
2021-03-01, 1399/12/11
Ethics committee reference number
IR.TBZMED.REC.1399.1147

Health conditions studied

1

Description of health condition studied
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Peak Plasma Concentration (Cmax), AUC (Area Under the Concentration-Time Curve)
Timepoint
At 0 (before intervention), 0.5، 1، 2، 3، 4، 5، 6، 8، 12، 24 ،48 ،72 ،96 and 120 hour after dosing
Method of measurement
High-performance liquid chromatography—mass spectrometry (HPLC-MS) and using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSSIntervention groups

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group (Test): Gefitinib 250 mg tablets, produced by Kimia pharmaceutical Co. is the test product. In each period, 15 of 30 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

2

Description
Intervention group (Reference): Gefitinib 250 mg tablets (produced by AstraZeneca co.) is the reference product. In each period, 15 of 30 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Drug Applied Research Center
Full name of responsible person
Dr Hamed Hamishehkar
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Fax
+98 41 3336 7914
Email
hamishehkar.hamed@gmail.com
Web page address
https://darc.tbzmed.ac.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Kimia pharmaceutical Co
Full name of responsible person
Esmaeil Moazeni
Street address
No. 1462, Bu Ali Biotechnology Park, Opposite North Campus, University of Tehran, North Kargar St., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1111111111
Phone
+98 21 8801 2946
Fax
+98 21 8822 0700
Email
mitra.movahedian@gmail.com
Web page address
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Kimia pharmaceutical Co
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Email
Hamishehkar.hamed@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Jaber Emami
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
Hezarjarib St., School of Pharmacy and Pharmaceutical Sciences , Isfahan, Iran
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3792 7111
Fax
+98 31 3668 0011
Email
Emami@pharm.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Fatima Molavi
Position
PhD student of Pharmaceutics
Latest degree
Medical doctor
Other areas of specialty/work
Pharmaceutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 2700
Fax
Email
Molavif@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Loading...